The mission of Lenima Field Diagnostics LLC is to improve healthcare by bringing revolutionary, groundbreaking molecular diagnostic tests to the forefront of medical care for infectious disease and cancer applications.

The revolutionary piezoelectric plate sensor (PEPS) technology that Lenima is based on is a result of more than ten years of collaborative effort between the founder, Dr. Wan Y. Shih, a biomedical engineer and the co-founder, Dr. Wei-Heng Shih, a materials engineer. This close collaborative effort allows them to create groundbreaking biomedical devices with unmatched performance by unleashing unique materials properties.

Revolutionary Molecular Diagnostic Tests from Lenima

Lenima offers revolutionary, groundbreaking molecular testing that can be brought to the point of care. The heart of Lenima's molecular diagnostic tests is a revolutionary piezoelectric plate sensor (PEPS) based on a novel thin crystalline material that allows unsurpassed sensitivity, simplifying the genetic testing process, permitting rapid and simultaneous testing of multiple nucleic acids including both DNAs and RNAs in a simple, elegant, portable, and low-cost format.

LFD’s first application is a rapid, low-cost, accurate and point-of-care Clostridium difficile infection (CDI) test. CDI is a leading healthcare associated infection (HAI), causing 14,000 deaths and costing $3B each year in the US. What makes CDI hard to combat is that 75% of CDI first occur outside of hospitals, mainly in nursing homes where there is no CDI genetic testing capability. Even small and medium-size hospitals (80% of the hospital market) also lack rapid CDI genetic testing capability due to cost. The inexpensive and yet accurate PEPS CDI test will allow multiplex, point-of-care CDI genetic testing with PCR-like sensitivity and specificity for small, medium hospitals and nursing homes, which with $20/kit, represents a $124 MM/year market in the US alone.